EM 574

Drug Profile

EM 574

Latest Information Update: 10 Oct 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer Nonindustrial source; Takeda
  • Class Antiulcers; Gastrokinetics
  • Mechanism of Action Motilin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gastritis; Gastro-oesophageal reflux

Most Recent Events

  • 10 Oct 2000 Discontinued-II for Gastritis in Japan (PO)
  • 10 Oct 2000 Discontinued-II for Gastro-oesophageal reflux in USA (PO)
  • 12 Jun 2000 Profile reviewed but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top